Analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX - Get Free Report) in a research report issued on Thursday. The firm set a "hold" rating on the stock.
Brooklyn ImmunoTherapeutics Stock Performance
Shares of NYSE BTX traded up $0.05 during mid-day trading on Thursday, reaching $6.72. The company had a trading volume of 1,156,180 shares, compared to its average volume of 822,645. Brooklyn ImmunoTherapeutics has a one year low of $6.57 and a one year high of $8.31. The firm has a market cap of $395.31 million, a price-to-earnings ratio of -2.96 and a beta of 4.61. The business's 50-day simple moving average is $2.01 and its 200 day simple moving average is $1.35.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Read More
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
